Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

The BuzzBuilding - How to Make London Self Sufficient in Protein trough Urban Insect Farming

The BuzzBuilding - Belatchew Arkitekter's proposal on how to make cities self-sufficient in protein through urban insect farming - is currently on display at the Roca London Gallery as part of the exhibition 'London 2026: recipes for building a food capital', a showcase of creative visions, architectural schemes and live projects from around the world that explore the sustainable integration of food into the urban mix. Roca’s spring exhibition is set in London in 2026, when the capital’s population will have passed the 10 million mark.  The show imagines how ‘agritecture’ –

SEK 100 million contribution to research

The Board of Södra has decided to allocate SEK 100 million to research, of which half will be earmarked for the development of forest management methods and technologies.“Society’s expectations of how this renewable raw material from the forest can help to combat climate change is clear. We are therefore investing to create opportunities for increasing forest production using low-impact methods in family forestry,” said Lars Idermark, President and CEO of Södra. The special R&D programme will take place during the period 2019-2022. The initiative is in line with Södra’s sustainability

NATTO: OPTIONS GRANTED

Oslo, Norway (13 February 2019) — Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 30th, 2018, and the option program related to defined operational objectives approved by the Board of Directors in 2018, the Board of Directors of NattoPharma has in board proceedings February 12th, 2019 granted a total of 292 500 options to executive management, other employees and strategic partners. Options are granted based on performance against defined criteria and metrics. The following persons on the executive management

Catena Media resolves upon a directed new share issue as payment for assets acquired in December 2017

The board of directors of Catena Media plc (“Catena Media” or the “Company”) has, under the authorization in the articles of association of the Company and in accordance with a press release on 4 December 2017, resolved upon a directed new issue of 468,132 shares at a subscription price of SEK 103.6742 per share, as payment of part of the upfront purchase price for acquired assets in Baybets  Ltd.On 4 December 2017 

Net sales exceeds SEK 1 billion and increased dividend

Summary for January–December 2018 ·  Net sales: SEK 1,017 million (855) ·  Profit after net financial items: SEK 116.8 million (98.1) ·  Operating margin: 12.6% (12.5) ·  Earnings per share before dilution: SEK 3.23 (2.70) ·  Cash flow from operating activities: SEK 197 million (188) ·  The Board of Directors propose a dividend increase to SEK 1.20 per share (1.10) Summary for October–December 2018 ·  Net sales: SEK 290 million (247) ·  Profit after net financial items: SEK 30.6 million (28.6) ·  Operating margin: 11.8% (12.6) ·  Earnings per share

Precise, controlled aerosols wet or dry: ISAB launches new nebulizer feature

From cystic fibrosis to antibiotics, work on new inhalable biologic therapies is growing. With biologics formulated as liquid solutions, the need for precisely controllable wet, as well as dry, aerosols is crucial. PreciseInhale’s new nebulizer feature meets the need, generating aerosol from liquids—and letting researchers choose to  deliver them as either wet or dry aerosols to PreciseInhale’s wide range of exposure modules.“Wet or dry aerosol isn’t really the question,” says ISAB CSO Per Gerde. “Precise aerosols and results—or not. That’s what’s really important for drug developers.”

Full Year Report January – December 2018

Q4: Strong sales and volumes for smokeless products · In local currencies, sales increased by 7 percent for the fourth quarter and by 9 percent for the full year. Reported sales increased by 12 percent to 3,301 MSEK (2,951) for the fourth quarter and by 10 percent to 12,966 MSEK (11,751) for the full year. · In local currencies, operating profit from product segments1) increased by 8 percent for the fourth quarter and by 12 percent for the full year. Reported operating profit from product segments increased by 14 percent to 1,246 MSEK (1,096) for the fourth quarter and by 14 percent

Notice to the holders of bonds issued by Ahlsell under the MTN programme

Notice to the holders of bonds issued by Ahlsell AB (publ) (”Ahlsell”) under Ahlsell’s MTN programme in relation the public tender offer to the shareholders of Ahlsell. Following the public tender offer to the shareholders of Ahlsell as of 11 December 2018 Quimper AB has on 13 February 2019 announced that Quimper AB completes the offer and thereby becomes owner of shares representing 93.9 per cent of the total number of shares and votes in Ahlsell. Quimper AB’s acquisition of the shares in Ahlsell constitutes a change of control event pursuant to the terms and conditions of Ahlsell AB’s

CORRECTION: Hexagon Composites ASA: Results for the fourth quarter 2018

This is a correction of the announcement from 07:00 13.02.2019 CET. Reason for the correction: Incorrect year reference to EBIT in the fourth quarter In the fourth quarter 2018 Hexagon Composites generated NOK 426.8 (358.5) million in operating income and made an operating profit before depreciation (EBITDA) of NOK 55.2 (39.9) million. Operating profit (EBIT) was NOK 19.2 (19.7) million and profit/loss before tax came to NOK 41.4 (2.2) million. EBIT in the fourth quarter 2018 was adversely impacted by an asset impairment adjustment of NOK 16.0 million. EBITDA for the quarter included a

TOMRA: Invitation to Q4 2018 presentation

TOMRA's fourth quarter 2018 results will be released Thursday 21st of February 2019. President & CEO Stefan Ranstrand and CFO Espen Gundersen will present the results at 08:00 CET. The presentation will be held in English and take place at Thon Hotel Vika Atrium, Oslo Norway (Meeting room: Nyland). The presentation will be webcasted live. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the presentation. A recorded version of the webcast will be available shortly after the webcast has concluded. Link to

NATTO: STRONG GROWTH AND POSITIVE RESULT

Oslo, Norway (13 February 2019) - NattoPharma increased revenues by 52% in the second half of the year and delivered a positive net result in the half year and for the full year 2018. This is coupled with a strong financial position with no interest-bearing debt and an equity ratio of 74,5% as at December 31st, 2018. “We are very pleased to deliver a strong second half fueled by a record fourth quarter with Product Revenues of approximately NOK 31 million and an EBITDA of 10%. This is the first full year where the Group has a positive net result, demonstrating our ambition of profitable

MUNTERS FOURTH QUARTER AND FULL YEAR 2018

Fourth quarter 2018 · Order intake decreased by 4% to SEKm 1,753 (1,821). The fourth quarter 2017 included a SEKm 450 Data Center order. · Net sales increased by 1% to SEKm 1,834 (1,811). · Operating profit (EBIT) amounted to SEKm -256 (127). · EBIT included a SEKm -323 write-down of goodwill related to Data Centers. · Adjusted EBITA decreased by 11% to SEKm 154 (174), corresponding to an adjusted EBITA margin of 8.4% (9.6). · Net income was SEKm -321 (152). · Cash flow from operating activities was SEKm 441 (-8). · Earnings per share amounted to SEK -1.78 (0.83).

Invitation to Essity’s Investor Day 2019

Essity, a leading global hygiene and health company, invites investors, analysts and media to an investor day in Stockholm on May 23, 2019. Presentations will be held by President and CEO Magnus Groth, other members of the Executive Management Team and representatives from Vinda.Essity’s vision is: Dedicated to improving well-being through leading hygiene and health solutions. During its investor day, Essity will describe its strategic work for achieving its vision and continuing to deliver profitable growth. The work on launching successful innovations, building our brands, improving

Vicore Pharma postpones publication of year-end report

Mölndal, February 13, 2019 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the year-end report for 2018. The year-end report will be published on March 15, 2019, instead of previously announced February 22, 2019.The reason for postponing the report is the decision to convert the company’s accounting principles to IFRS as per the year-end report for 2018. Conversion to IFRS is an important part of the preparations for the up-listing to the Stockholm Nasdaq main list which is planned to take place during the second half of 2019. For further information, please

Year-end report 2018

Net sales increased sharply during the quarter to SEK 37.8 million (11.1) due to increased deliveries. Net sales for the full year amounted to SEK 58.9 million (11.9). Order intake for the fourth quarter amounted to SEK 40.0 million (12.6). In total, the order backlog amounted to SEK 818.6 million (353.7) by the end of the year. During the quarter many modules have been delivered to customers within Maritime. Within the geothermal segment, focus continues to be on Japan and Iceland, where Varmaorka is now conducting final tests of their first power plant which has begun delivering electricity

Q4 2018: Growth in fourth quarter closes the year

Significant events in the fourth quarter• Fourth-quarter net sales rose to MSEK 163, up 36%, or MSEK 43 compared with the year-on-year period, due to continued recovery from a customer-specific destocking programme• First commercial order after the introduction of Probi’s product to improve bone health in postmenopausal women – Probi® Osteo• Promising initial results from clinical trials to evaluate the effects of Probi’s strains on physical performance and acute stress• Tom Rönnlund appointed new CEO as of January 1, 2019 and Henrik Lundkvist new CFO as of January 7, 2019• Board

Chanel store expansion in Stockholm

During 2019, Chanel will expand its store space in the Hufvudstaden property at Birger Jarlsgatan 7 in Bibliotekstan. The store will increase in size from the current 200 square metres to around 500 square metres spread over two floors. The newly expanded store is expected to open in autumn 2019.  “Hufvudstaden’s aim is to offer successful retail and office tenants prime business locations in central Stockholm and central Gothenburg. We are therefore extremely pleased that Chanel has chosen to broaden its operations in a Hufvudstaden property in Bibliotekstan,” says Ivo Stopner,

Correction of error Q3 (18) report

Lund, Sweden, 08.00 CET, February 13, 2019 - BONESUPPORT ™, an emerging leader in orthobiologics for the management of bone voids, today announces that the report for the third quarter of 2018, published November 7, 2018, contained an error that arose in connection with the transition to a new reporting system. Due to the error, gross profit and the result for the third quarter of 2018 have been reported as SEK 1.3 million too high. The error relates in its entirety to the segment EUROPE & REST OF WORLD. The error refers to internal profit calculation in inventories and was discovered

There are no items matching the current filter
There are no more items matching the current filter
Back to top